The NuVasive anterior cervical plate (ACP) system is designed to achieve your ACDF surgical goals and help reduce dysphagia, malalignment and adjacent level ossification. ACP is procedurally integrated with versatile instrumentation, a complete interbody portfolio featuring advanced porous materials, traditional PEEK and allograft, biologics, the Maxcess C retractor and enabling technologies.
Features:
- Plate stiffness and profile
- Optimized for every level.
- Construct stability options.
- Plate length
- Array of implant options.
- Made for unique patient needs.
- Plate confirmation
- Advanced screw offering.
- Locking that enables confidence.
About Nuvasive
NuVasive, Inc. (NASDAQ: NUVA) based in San Diego, California, is a medical device company focused on the design, development, and marketing of products for the surgical treatment of spine disorders. NuVasive’s product portfolio is focused on applications in the over $4.2 billion U.S. spine fusion market. The Company’s current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS, as well as a growing offering of cervical and motion preservation products. NuVasive® is a medical device company focused on developing minimally disruptive surgical products and procedurally integrated solutions for the spine.
The Company is the third largest medical device company in the $8.2 billion global spine market. NuVasive’s principal product offering is based on its Maximum Access Surgery, or MAS® platform. The MAS platform combines several categories of solutions that collectively minimize soft tissue disruption during spine surgery with maximum visualization and safe, easy reproducibility for the surgeon: a proprietary software-driven nerve avoidance system and intra-operative monitoring support; MaXcess®, a unique split-blade retractor system; a wide variety of specialized implants; and several biologic products to aid in the spinal fusion process. MAS significantly reduces surgery time and returns patients to activities of daily living much faster than conventional approaches.
With over 90 products today spanning lumbar, thoracic and cervical applications, the Company will continue to expand and evolve its offering predicated on its R&D focus. http://www.nuvasive.com